As of 2025-04-23, the Intrinsic Value of Trillium Therapeutics Inc (TRIL.TO) is 0.79 CAD. This TRIL.TO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 23.33 CAD, the upside of Trillium Therapeutics Inc is -96.60%.
The range of the Intrinsic Value is 0.65 - 0.85 CAD
Based on its market price of 23.33 CAD and our intrinsic valuation, Trillium Therapeutics Inc (TRIL.TO) is overvalued by 96.60%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 0.65 - 0.85 | 0.79 | -96.6% |
| DCF (Growth 10y) | 0.85 - 0.68 | 0.79 | -96.6% |
| Fair Value | -3.68 - -3.68 | -3.68 | -115.76% |
| P/E | (13.49) - (15.92) | (15.07) | -164.6% |
| EPV | (3.30) - (4.39) | (3.85) | -116.5% |
| DDM - Stable | (3.35) - (8.09) | (5.72) | -124.5% |
| DDM - Multi | (0.08) - (0.15) | (0.10) | -100.4% |
| Market Cap (mil) | 2,607.01 |
| Beta | 1.96 |
| Outstanding shares (mil) | 111.75 |
| Enterprise Value (mil) | 2,477.90 |
| Market risk premium | 4.74% |
| Cost of Equity | 14.25% |
| Cost of Debt | 5.00% |
| WACC | 9.62% |